|Alt. symbols||CD27LG, TNFSF7|
|Locus||Chr. 19 p13|
CD70 (Cluster of Differentiation 70) is a ligand for CD27.
The CD70 protein is expressed on highly activated lymphocytes (like in T- and B-cell lymphomas). It is therefore suggested that anti-CD70 antibodies might be a possible treatment for CD70 positive lymphomas as normal lymphocytes have low CD70 expression.
ARGX-110 is a CD70-specific antibody that is currently under investigation for the treatment of hematological malignancies. It is being developed by the Belgian company arGEN-X. In December 2013 a first part of a phase 1b trial was completed. In January 2014 a safety and efficacy phase of the study started.
- Israel BF, Gulley M, Elmore S, Ferrini S, Feng WH, Kenney SC (2005). "Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas". Mol. Cancer Ther. 4 (12): 2037–44. doi:10.1158/1535-7163.MCT-05-0253. PMID 16373719.
- "ARGX-110: first-in-class CD70-targeting antibody with unique mode of therapeutic action". arGEN-X. Retrieved 28 February 2015.
- Seattle Genetics Third Quarter 2013 Financial Report
|File:Beta-2 adrenergic receptor.png||This membrane protein–related article is a stub. You can help Wikipedia by expanding it.|